Drug Profile
Lu AF35700
Alternative Names: Lu-AF35700Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Class Neuropsychotherapeutics
- Mechanism of Action Dopamine D1 receptor modulators; Serotonin 5-HT2A receptor modulators; Serotonin-6 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Schizoaffective disorder; Schizophrenia
Most Recent Events
- 10 Oct 2019 Lundbeck A/S completes the phase III Debut trial for Schizophrenia (Treatment-resistant) in USA, Canada, Bulgaria, Czech Republic, Estonia, Mexico, Poland, Romania, Russia, Serbia, Slovakia, Spain and Ukraine (NCT02892422)
- 26 Sep 2019 H. Lundbeck A/S terminates a phase I trial in Schizophrenia (In volunteers) in Germany based on new efficacy data (PO) (NCT03241147)
- 14 Aug 2019 Discontinued - Phase-I for Schizoaffective disorder in USA (PO)